RESUMO
Capnocytophaga canimorsus (CC) belongs to the family Flavobacteriaceae which physiologically occurs in the natural flora of the oral mucosa of dogs and cats. In patients with a compromised immune system, CC can induce a systemic infection with a fulminant course of disease. Infections with CC are rare, and the diagnosis is often complicated and prolonged. We describe a patient with a medical history of prior splenectomy who presented with an acute sepsis and disseminated intravascular coagulation (DIC) and was initially treated on Waterhouse-Friderichsen syndrome (WFS). After the patient had died despite forced treatment in the intermediate care unit, the differential diagnosis of CC was confirmed by culture of blood smears. Later on, a retrospective third-party anamnesis revealed that the patient had contact to his neighbour's dog a few days before disease onset. In conclusion, patients with CC infection can mimic WFS and therefore must be included in the differential diagnosis, especially in patients with a corresponding medical history of dog or cat bites, scratches, licks, or simple exposure.
RESUMO
A previously undescribed, slowly growing Mycobacterium species was isolated from pulmonary specimens of two patients, one from Denmark and one from Italy. The isolates showed unique 16S rRNA internal transcribed spacers and hsp65 sequences: the 16S rRNA was most closely related to Mycobacterium szulgai and Mycobacterium malmoense.
Assuntos
Pneumopatias/microbiologia , Mycobacterium/isolamento & purificação , Idoso , Sequência de Bases , DNA Espaçador Ribossômico/genética , Humanos , Masculino , Dados de Sequência Molecular , Mycobacterium/classificação , Mycobacterium/genética , RNA Ribossômico 16S/genéticaRESUMO
Procedeu-se a uma avaliaçäo duplo-cega de fentiazac contra placebo em 60 pacientes com sinusite aguda ou crônica em agudizaçäo (30 em cada grupo). O fentiazac foi empregado na forma de uma drágea de 100mg de 6/6 horas, sendo o placebo indistinguível e administrado em iguais intervalos. O tratamento foi mantido por 10 dias. O fentiazac proporcionou melhora estatisticamente significante dos principais sintomas (dor, rinorréia, piofagia, obstruçäo nasal, hipo ou anosmia e mal-estar geral), o que näo verificou com placebo. O efeito da fentiazac foi superior ao do placebo a nível estatisticamente significante na maioria dos sintomas e no resultado global. A tolerabilidade foi boa e equivalente em ambos os grupos. Os autores concluem pela utilidade do fentiazac na sinusites
